<?xml version="1.0" encoding="UTF-8"?>
<p id="Par29">Thus, the decision by the FDA to bypass animal trials is taken positively by entrepreneurs. According to them, flexibility of laws by the FDA could avoid delays in treating, as observed in the case of ganciclovir. Although ganciclovir is successful in treating patients with acquired immunodeficiency syndrome-related cytomegalovirus retinitis, due to lack of animal studies, it did not get approval by FDA and was delayed by 4 years (Van Norman 
 <xref ref-type="bibr" rid="CR35">2019</xref>).
</p>
